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ficients were used to assess the level of association. RE-
SULTS: 81 patients participated in the study. Mean age
of the sample was 57.3 (SD  10.1) years, 89% (n  72)
were female. The average disease duration among pa-
tients was 14.5 (SD  10.6) years. RAQoL scores were
relatively strongly correlated (Pearson coefficient  0.662)
with HAQ scores. The EQ-5D index scores showed higher
correlation (0.627) with HAQ than the Visual Analogue
Scale of EQ-5D (0.463). The Pearson Correlation Coeffi-
cient between RAQoL and EQ-5D index scores was
0.515, and between RAQoL and EQ-5D VAS scores was
0.396. CONCLUSIONS: Results suggest that the Hun-
garian RAQoL is a valid instrument of measuring QoL of
rheumatoid arthritis patients. The EQ-5D index provides
also appropriate results, and can be proposed for cost-
utility analyses. However EQ-5D VAS scores are not rec-
ommended to describe the QoL of patients with rheuma-
toid arthritis.
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COST-EFFECTIVENESS OF ROFECOXIB VERSUS 
NSAIDS IN THE TREATMENT OF 
OSTEOARTHRITIS
Sullivan P, Hay J
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: The purpose of this study is to examine
the cost-effectiveness (CE) of rofecoxib versus NSAIDs in
the treatment of osteoarthritis. METHODS: The authors
used decision-analysis from a societal perspective to
model a hypothetical cohort of osteoarthritis patients on
long-term NSAID therapy. Incremental cost per QALY
(C/QALY) estimates were calculated for a hypothetical
trial population and for patients at high risk of G.I. ad-
verse events. High-risk patients were defined in the litera-
ture as having four risk factors combined: history of G.I.
bleeds, history of peptic ulcer, cardiovascular disease and
age 75 years or greater. All costs were expressed in 1997
prices. Utility estimates were obtained from a separate
analysis of pharmacy claims data including the Health
Utilities Index Mark 2 from a large HMO. Confidence
intervals were assessed using the maximum and mini-
mum values from the literature. Univariate sensitivity and
threshold analysis were conducted. RESULTS: The C/
QALY range is $5,658 to $108,831 for osteoarthritis pa-
tients; base case C/QALY is $103,597 for all osteoarthri-
tis patients, $9,374 for high-risk patients. Rofecoxib is
cost-effective (C/QALY $50,000) if the incidence of
perforations, ulcers and bleeds (PUB) is 0.098 per year or
greater. Sensitivity: the most sensitive parameters were:
symptomatic dyspepsia utility; rofecoxib price; symptom-
atic peptic ulcer utility; incidence of G.I. symptoms;
NSAID price and incidence of PUBs. However, the pa-
rameters with greatest uncertainty and variability in the
literature are incidence of PUBs and G.I. symptoms.
CONCLUSION: The point estimate C/QALY of rofe-
coxib for all osteoarthritis patients varies from very cost-
effective to not cost-effective depending on assumptions
for the probability of PUBs and G.I. symptoms. Rofe-
coxib is cost saving for patients at high risk of developing
G.I. complications.
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RHEUMATOID ARTHRITIS PATIENTS
Lubeck DP1, Yelin E1, Katz P1, Roepke L1, Wanke LA2, Buatti M3
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OBJECTIVE: To evaluate the correlation between gen-
eral measures of function and well-being, as measured by
the 8 domains of the SF-36, with arthritis specific mea-
sures of function and symptom frequency. METHODS:
We identified 606 patients from a longitudinal, observa-
tional study of RA (RAPOLO). Patients completed tele-
phone interviews about arthritis specific function (HAQ,
RA Status and Symptoms), the SF-36 domains, Physical
and Mental Summary Scores (PCS, MCS) and the Arthri-
tis Specific Health Index (ASHI). We present correlations
between the SF-36 domains, PCS, MCS and ASHI with
selected arthritis measures. All correlations are presented
as absolute values. RESULTS: All correlations were in
the anticipated direction. A correlation 0.6  good–ex-
cellent, and 0.4  below average. The HAQ was highly
correlated with the SF-36 physical scales, and had weak
correlations with the emotional function scales and the
ASHI. Other arthritis specific scales (joint swelling, joint
pain, morning stiffness, RA fatigue and RA pain) were
strongly correlated with the ASHI, the SF-36 pain, physi-
cal function, role function-physical and energy/fatigue
scales; and had weak correlations with the emotional
functioning and general health scales. CONCLUSIONS:
In RA patients, the SF-36 measures aspects of functioning
and well-being not covered by the arthritis specific mea-
sures, especially in the areas of emotional functioning.
This is indicated by the moderate to weak correlations
between the arthritis specific measures and the domains
of emotional function, role emotional function, and men-
tal health and the MCS.
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COST COMPARISON OF TREATING 
OSTEOPOROSIS PATIENTS WITH ESTROGENS 
OR SELECTIVE ESTROGEN RECEPTOR 
MODULATOR IN A MANAGED CARE 
POPULATION
Liao E, Sweazy L, Huse D
PharMetrics, Inc, Watertown, MA, USA
OBJECTIVE: To compare osteoporosis treatment charges
among patients treated with an estrogen versus a selective
estrogen receptor modulator (SERM) in a managed care
population. METHODS: Patients 40 years of age with a
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diagnosis of osteoporosis between January 1 and June
30, 1999 and 2 pharmacy claims for an estrogen or
SERM were selected from the PharMetrics Integrated
Outcomes Database. Patients were excluded if they had
less than 6 months of continuous enrollment following
the first (index) prescription claim for an estrogen or
SERM or received other drugs for osteoporosis, such as
bisphosphonates or calcitonin-salmon. The frequency of
of hip, vertebral, forearm/wrist or other fracture and/or
related surgical procedures and osteoporosis-specific
charges were assessed over the 6-month period following
the index prescription. RESULTS: 252,892 patients met
the selection criteria, including 245,650 treated with es-
trogen and 7,242 with SERMs. The estrogen cohort was
significantly younger than the SERM cohort (mean age:
54.3 vs. 59.0 years, p  0.001) and had less frequent
fractures/surgical procedures (1.0% vs. 1.6%, p  0.001).
The SERM group had higher mean osteoporosis-related
pharmacy ($309 vs. $106) and medical charges ($73 vs.
$29) resulting in a total charge difference of $247 (p 
0.001). Stratified analyses indicated that the SERM co-
hort had consistently higher mean charges across all age
ranges compared to the estrogen cohort. CONCLUSION:
In this initial cost comparison between SERM and estro-
gen therapy for osteoporosis, short-term (6-month) os-
teoporosis-related charges were significantly higher in the
SERM group primarily due to the difference in drug
costs. Longer-term studies are required to examine all of
the costs associated with these therapies.
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COST COMPARISON OF TREATING 
RHEUMATOID ARTHRITIS PATIENTS WITH 
COX-2 INHIBITORS OR NSAIDS IN A MANAGED 
CARE POPULATION
Liao E, Kester G, Huse D
PharMetrics, Inc, Watertown, MA, USA
OBJECTIVE: To compare rheumatoid arthritis (RA)
treatment charges with a cyclooxygenase-2 specific inhib-
itor (COX-2) versus a non-steroidal anti-inflammatory
drug (NSAID) therapies in a managed care population.
METHODS: Patients with a diagnosis of RA between
January 1 and June 30, 1999 who had prescriptions for
COX-2s or NSAIDs were selected from the PharMetrics
Integrated Outcomes Database. Patients were excluded if
they had osteoarthritis or did not have 6 months of con-
tinuous enrollment following the first (index) COX-2 or
NSAID pharmacy claim. COX-2 and NSAID-treated
groups were compared on their demographics, comorbid-
ities, and total RA-specific charges during the 6 month
follow-up period RESULTS: A total of 5,261 patients
met the patient selection criteria, including 668 who re-
ceived COX-2 and 4,593 who received NSAID. The
COX-2 group was older (53.7 versus 49.6 years, p 
0.0001) on average and more likely to have at least one
comorbidity (46.0% vs. 31.9%, p  0.001) compared to
the NSAID group. They also had higher RA-related phar-
macy ($914 versus $636) and medical charges ($611 ver-
sus $566). Total mean charges for the COX-2 cohort
were $323 higher (p  0.019) than the NSAID cohort.
CONCLUSION: In this initial cost comparison between
COX-2s and NSAIDs, the mean charge for a 6-month pe-
riod with COX-2s was 27% higher than with NSAIDs,
mainly due to higher pharmacy charges. Longer-term
studies are required to examine whether the higher acqui-
sition costs of COX-2 are offset by savings in the costs of
treating gastrotoxicity.
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THE IMPACT OF EARLY RHEUMATOID 
ARTHRITIS ON PRODUCTIVITY
Kim SS, Drabinski AM, Williams GR, Formica CA
Knoll Pharmaceutical Company, Mount Olive, NJ, USA
BACKGROUND: Rheumatoid arthritis (RA) leads to phys-
ical and psychosocial functional disabilities affecting pro-
ductivity of patients in their daily activities. OBJECTIVE:
to evaluate the impact of early RA on productivity.
METHODS: Baseline data was analyzed from the Study
of New Onset Rheumatoid Arthritis (S.O.N.O.R.A.SM),
a five-year prospective, longitudinal, inception-cohort
study to document long-term functional, clinical, and hu-
manistic outcomes and patterns of treatment in patients
with new onset RA. Telephone interviews were per-
formed by trained interviewers to collect data on employ-
ment status, annual household income (AHI) and pro-
ductivity at work and normal activities, outside of paid
job (NAOPJ), including absenteeism over the past 4
months, reason for absenteeism, and effectiveness at
work and NAOPJ when working with arthritis symptoms
(AS). RESULTS: One hundred thirty one patients com-
pleted the baseline survey. Mean age was 56  15 years;
78% were female; 82% were Caucasian. Employment
status reported was full-time (52%), part-time (2%), re-
tired (26%), and other (20%). AHI were $50,000
(63%), $50,000–74,999 (17%), $75,000 (18%), and
2% refused to provide AHI. Ninety-one percent of pa-
tients were employed at a paid job. The mean absentee-
ism at work and NAOPJ were 4.3 days (SE  1.1) and
25.9 days (SE  3.3), respectively. Of the participants re-
porting absenteeism, 40% and 69% reported that the
majority of absenteeism was due to AS for work and
NAOPJ, respectively. Compared to their normal perfor-
mance, patients were 78% and 64% as effective when
working with AS at work and NAOPJ, respectively.
CONCLUSION: Despite new onset of RA in this popula-
tion, negative impact on productivity was observed. A
greater decline in productivity was reported for NAOPJ.
This may imply that NAOPJ is compromised before
work activities in early RA patients. Five-year follow-up
of this population will provide further insight on produc-
tivity changes and the economic burden associated with
progressive disease.
